Colostrum From MERS-CoV Seropositive Camels for SARS-CoV-2 Infection - a Placebo-controlled Rando… (NCT06857318) | Clinical Trial Compass
CompletedPhase 1/2
Colostrum From MERS-CoV Seropositive Camels for SARS-CoV-2 Infection - a Placebo-controlled Randomized Trial.
Israel43 participantsStarted 2023-05-01
Plain-language summary
The study aims to study the efficacy of colostrum from MERS-CoV-positive camels applied as a nasal spray to COVID-19 patients for treatment and prevention of SARS-CoV-2 infection. This study will compare the usage of colostrum to placebo.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age over 18 years.
* Laboratory-proven infection with COVID-19 using PCR or another approved kit
* Hospitalized / community setting-at low-moderate clinical risk according to the NEWS-2 scale with a score of 0-10.
* Onset of symptoms up to 7 days before inclusion
* Can sign informed consent
* Willingness and ability to participate in research
Exclusion Criteria:
* Pregnant women or lactating
* Lack of judgment (psychiatric disorder or dementia)
* Immunosuppressed - HIV with CD4 below 500, chemotherapy, steroids - more than 5 mg per day, solid organ transplants, bone marrow transplants, active hematological or oncological malignancies, biological therapy
* Neutropenia (less than 2000 neutrophils per cubic meter) or thrombocytopenia (platelet count less than 50000 per cubic meter).
* Acute or chronic sinusitis.
* Nasal polyps or any pathology in the nasal cavity
* Cystic fibrosis
* Significant disturbance in liver functions (AST/ALT more than 5 times the ULN)
* Significant renal dysfunction (GFR lower than 30 ml per minute)
* Known allergy to colostrum or cow\'s milk
* Use of another study drug